p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents
…, N Kong, LI Ye, W Han, J Zhou, Q Zhang, C He, H Pan - Cancer letters, 2014 - Elsevier
The Mitogen Activated Protein Kinase (MAPK) signaling plays a critical role in the outcome
and the sensitivity to anticancer therapies. Activated MAPK can transmit extracellular signals …
and the sensitivity to anticancer therapies. Activated MAPK can transmit extracellular signals …
The role of STAT3 in autophagy
…, Z Wang, H Li, J Shou, Z Jing, J Xie, X Sui, H Pan… - Autophagy, 2015 - Taylor & Francis
Autophagy is an evolutionarily conserved process in eukaryotes that eliminates harmful
components and maintains cellular homeostasis in response to a series of extracellular insults. …
components and maintains cellular homeostasis in response to a series of extracellular insults. …
[HTML][HTML] CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer
…, Y Zheng, J Sheng, Y Han, Y Yang, H Pan… - Frontiers in …, 2022 - frontiersin.org
The crucial role of CD4 + and CD8 + T cells in shaping and controlling immune responses
during immune disease and cancer development has been well established and used to …
during immune disease and cancer development has been well established and used to …
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo …
…, Y Sun, H Liang, J Liu, J Wang, WY Tak, H Pan… - The lancet …, 2009 - thelancet.com
Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where
chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and …
chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and …
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a …
Background In the international randomised phase 3 CORRECT trial (NCT01103323),
regorafenib significantly improved overall survival versus placebo in patients with treatment-…
regorafenib significantly improved overall survival versus placebo in patients with treatment-…
[PDF][PDF] Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
…, C Wang, T Dai, T Mao, L Chen, Z Guo, B Liu, H Pan… - Cancer cell, 2022 - cell.com
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
[HTML][HTML] Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial
…, S Qin, WT Huang, IJ Chung, H Pan… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
… Provision of study materials or patients: Calin Cainap, Hongming Pan, Ying Cheng, Yoon-Koo
Kang, Vera Gorbunova Collection and assembly of data: Shukui Qin, Wen-Tsung Huang, Ik …
Kang, Vera Gorbunova Collection and assembly of data: Shukui Qin, Wen-Tsung Huang, Ik …
[HTML][HTML] Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase …
…, Z Wang, J Ying, Y Lu, Z Meng, H Pan… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative,
has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study …
has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study …
[PDF][PDF] BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in …
…, H Zhang, G Cheng, X Song, Y Lu, H Pan… - Journal of clinical …, 2015 - researchgate.net
… Hongming Pan … Center for Respiratory Disease, State Key Laboratory of Respiratory
Disease, Guangzhou; Gongyan Chen, Harbin Medical University Cancer Hospital, Harbin; …
Disease, Guangzhou; Gongyan Chen, Harbin Medical University Cancer Hospital, Harbin; …
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
…, J Sandoval-Tan, Y Zhu, M Liao, C Zhou, H Pan… - The lancet …, 2013 - thelancet.com
Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study,
showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free …
showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free …